GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need

13.11.24 14:55 Uhr

New data shows potential for sequential therapy of bepirovirsen after daplusiran/tomligisiran to further increase functional cure rates.GlaxoSmithKline plc (GSK)">Weiter zum vollständigen Artikel bei GlaxoSmithKline plc (GSK)

Quelle: EN, GlaxoSmithKline

Nachrichten zu GlaxoSmithKline PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs